PI-103 (Standard)

PI-103 (Standard) is the analytical standard of PI-103. This product is intended for research and analytical applications. PI-103 is a potent PI3K and mTOR inhibitor with IC50s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for p110α, p110β, p110δ, p110γ, mTORC1, and mTORC2. PI-103 also inhibits DNA-PK with an IC50 of 2 nM. PI-103 induces autophagy[1][2][3][4].

Product Specifications

CAS Number

[371935-74-9]

UNSPSC

12352005

Target

Apoptosis; Autophagy; DNA-PK; mTOR; PI3K; Reference Standards

Related Pathways

Apoptosis; Autophagy; Cell Cycle/DNA Damage; Others; PI3K/Akt/mTOR

Field of Research

Cancer

Smiles

OC1=CC(C2=NC3=C(C(N4CCOCC4)=N2)OC5=C3C=CC=N5)=CC=C1

Molecular Formula

C19H16N4O3

Molecular Weight

348.36

References & Citations

[1]Raynaud FI, et al. Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther. 2009 Jul;8 (7) :1725-39.|[2]Park S, et al. PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase anLeukemia. 2008 Sep;22 (9) :1698-706.d mTOR, has antileukemicactivity in AmL. Leukemia. 2008 Sep;22 (9) :1698-706.|[3]López-Fauqued M, et al. The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of melanoma cells. Int J Cancer. 2010 Apr 1;126 (7) :1549-61.|[4]Knight ZA, et al. A pharmacological map of the PI3-K family defines a role for p110 alpha. Cell. 2006 May 19;125 (4) :733-47.